Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 May 1;30(5):480-489.
doi: 10.1097/GME.0000000000002167. Epub 2023 Feb 20.

A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2-vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life

Ulysse Gaspard  1 , Mélanie Taziaux  2 , Maud Jost  2 , Herjan J T Coelingh Bennink  3 , Wulf H Utian  4 , Rogerio A Lobo  5 , Jean-Michel Foidart
Affiliations
Randomized Controlled Trial

A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2-vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life

Ulysse Gaspard et al. Menopause. .

Abstract

Objective: A phase 2 study showed that 15 mg estetrol (E4) alleviates vasomotor symptoms (VMS). Here, we present the effects of E4 15 mg on vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life.

Methods: In a double-blind, placebo-controlled study, postmenopausal participants (n = 257, 40-65 y) were randomized to receive E4 2.5, 5, 10, or 15 mg or placebo once daily for 12 weeks. Outcomes were the vaginal maturation index and maturation value, genitourinary syndrome of menopause score, and the Menopause Rating Scale to assess health-related quality of life. We focused on E4 15 mg, the dose studied in ongoing phase 3 trials, and tested its effect versus placebo at 12 weeks using analysis of covariance.

Results: Least square (LS) mean percentages of parabasal and intermediate cells decreased, whereas superficial cells increased across E4 doses; for E4 15 mg, the respective changes were -10.81% ( P = 0.0017), -20.96% ( P = 0.0037), and +34.17% ( P < 0.0001). E4 15 mg decreased LS mean intensity score for vaginal dryness and dyspareunia (-0.40, P = 0.03, and -0.47, P = 0.0006, respectively); symptom reporting decreased by 41% and 50%, respectively, and shifted to milder intensity categories. The overall Menopause Rating Scale score decreased with E4 15 mg (LS mean, -3.1; P = 0.069) and across doses was associated with a decreasing frequency and severity of VMS ( r = 0.34 and r = 0.31, P < 0.001).

Conclusions: E4 demonstrated estrogenic effects in the vagina and decreased signs of atrophy. E4 15 mg is a promising treatment option also for important menopausal symptoms other than VMS.

Trial registration: ClinicalTrials.gov NCT04209543 NCT02834312.

PubMed Disclaimer

Conflict of interest statement

Financial disclosure/conflicts of interest: M.T. and M.J. are employees, U.G. and J.-M.F. are consultants, and W.H.U. and R.A.L. are members of the Scientific Advisory Board of Mithra Pharmaceuticals. W.H.U. received funding from Pharmavite, Los Angeles. H.J.T.C.B. is president and CEO of Pantarhei Bioscience.

Figures

FIG. 1
FIG. 1
Vaginal MV at baseline and at W12 (LOCF). One participant was randomized to E4 15 mg but temporarily took E4 2.5 mg and was excluded from the analysis. One participant was randomized to E4 2.5 mg and temporarily took E4 10 mg but was included in the 2.5 mg group for the analysis. *P < 0.001 versus placebo, analysis of covariance with fixed factors treatment and pooled site and covariate baseline value, including pairwise comparisons versus placebo (with adjustment for multiple comparisons according to Dunnett). E4, estetrol; LOCF, last observation carried forward; W12, week 12; MV, maturation value.
FIG. 2
FIG. 2
Mean shift at W12 (minus baseline values) of the percentage of participants reporting no, mild, moderate, or severe vaginal dryness (A) or vaginal pain with sexual activity (B) in the E4 2.5, 5, 10, and 15 mg and placebo groups and for all participants (total) (LOCF). One participant was randomized to E4 15 mg but temporarily took E4 2.5 mg and was excluded from the analysis. One participant was randomized to E4 2.5 mg and temporarily took E4 10 mg, but was included in the 2.5 mg group for the analysis. E4, estetrol; LOCF, last observation carried forward.
See this image and copyright information in PMC

References

    1. Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause — global prevalence, physiology and implications. Nat Rev Endocrinol 2018;14:199–215. doi: 10.1038/nrendo.2017.180 - DOI - PubMed
    1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94. doi: 10.4065/mcp.2009.0413 - DOI - PMC - PubMed
    1. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology 2003;62(4 Suppl 1):45–51. doi: 10.1016/s0090-4295(03)00676-9 - DOI - PubMed
    1. Portman DJ Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel . Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Menopause 2014;21:1063–1068. doi: 10.1097/GME.0000000000000329 - DOI - PubMed
    1. Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc 2017;92:1842–1849. doi: 10.1016/j.mayocp.2017.08.019 - DOI - PubMed

Publication types

Associated data